Las Vegas, NV -- (SBWIRE) -- 01/06/2014 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Penn National Gaming, Inc(NASDAQ:PENN), Cypress Semiconductor Corporation(NASDAQ:CY), Myriad Genetics, Inc.(NASDAQ:MYGN), Orexigen Therapeutics, Inc.(NASDAQ:OREX)
Penn National Gaming, Inc(NASDAQ:PENN) was a volume gainer of 1.90 million shares and the average volume of the stock remained 1.52 million shares. The stock opened the session at $14.22 and finished at the end of the day at $14.06 and the stock plunged -0.71%.The market capitalization of the stock remained 1.09 billion. Penn National Gaming, Inc., together with its subsidiaries, owns and manages gaming and pari-mutuel properties in the United States and Canada. It engages in gaming on slot machines and table games. Penn National Gaming, Inc. was founded in 1972 and is based in Wyomissing, Pennsylvania.
Has PENN Found The Bottom And Ready To Gain Momentum? Find Out Here
In the preceding trading session, Cypress Semiconductor Corporation(NASDAQ:CY) exchanged 1.89 million shares and the average volume remained 2.09 million shares. The stock closed the session at $10.42 with the gain of 1.36%. Cypress Semiconductor Corporation, together with its subsidiaries, designs, develops, manufactures, and markets mixed-signal, programmable solutions, specialized semiconductor memories, and integrated semiconductor solutions. Cypress Semiconductor Corporation founded in 1982 and is headquartered in San Jose, California.
Will CY Continue To Move Higher? Find Out Here
Myriad Genetics, Inc.(NASDAQ:MYGN) decreased -2.39% and its closing price was $21.20. The volume of the stock was 1.87 million shares and the average volume remained 2.69 million shares. The market capitalization of the stock remained 1.62 billion. The beta of the stock remained 0.45. Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Will MYGN Get Buyers Even After The Recent Rally? Find Out Here
Orexigen Therapeutics, Inc.(NASDAQ:OREX) exchanged 1.78 million shares in the previous trading session, and its average trading remained 42.06 million shares. OREX dropped -0.69% and it closed the trading at $5.75. The market capitalization of the stock remained 582.90 million. Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include Contrave, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic, which has completed Phase II clinical trials.
Has OREX Found The Bottom and Ready To Move Up? Find Out Here
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)